Back to results
US 2013/0296397 A1Published application
Early marker of proteinuria in patients treated with an anti-vegf treatment
AssigneeMayo Foundation for Medical Education and Research
InventorVesna D. Garovic
Life of this patent
Estimating the term…
Abstract
This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided.
Claims8
1-30. (canceled)
A method for treating a human with an anti-VEGF therapy or an anti-EFGR therapy, wherein said method comprises:
- (a) administering an initial dose of said anti-VEGF therapy or said anti-EFGR therapy to said human,
- (b) obtaining a urine sample from said human receiving said anti-VEGF therapy or said anti-EFGR therapy,
- (c) contacting podocytes within said urine sample with an antibody that binds to podocytes or polypeptides expressed by podocytes to form podocyte-antibody complexes,
- (d) performing flow cytometry to detect the presence of said podocyte-antibody complexes, and
- (e) administering a subsequent dose of said anti-VEGF therapy or said anti-EFGR therapy to said human, wherein said subsequent dose is at least 30 percent lower than said initial dose.
2 more elements
Dependencies are inferred from the claim text.